FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
美国食品药品管理局批准 KEYTRUDA 作为 IB 期(T2a ≥4 cm)、II 或 IIIA 期非小细胞肺癌 (NSCLC) 患者在手术切除和铂类化疗后的辅助治疗
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA批准KEYTRUDA作为手术切除和以铂为基础的化疗后的辅助治疗,用于IB期(T2â‰元4厘米)、II期或IIIA期非小细胞肺癌患者